Drug Shortage Report for VOLUVEN
| Report ID | 137619 |
| Drug Identification Number | 02278057 |
| Brand name | VOLUVEN |
| Common or Proper name | Voluven® (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) 500 mL |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | HYDROXYETHYL STARCH 130/0.4 |
| Strength(s) | 6% |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 500 mL |
| ATC code | B05AA |
| ATC description | BLOOD AND RELATED PRODUCTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2021-04-16 |
| Actual start date | 2021-04-16 |
| Estimated end date | 2021-07-01 |
| Actual end date | 2021-06-23 |
| Shortage status | Resolved |
| Updated date | 2021-06-24 |
| Company comments | Fresenius Kabi Canada Ltd. regrets to advise that due to a production delay, we will be encountering a supply interruption on our Voluven® 500 mL effective immediately until July 1st, 2021. Please note that our remaining inventory is short-dated with less than 1 month dating, and expires on April 30, 2021. Our Voluven® 250 mL and Volulyte® 500 mL formats are available for substitution. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2021-06-24 | English | Compare |
| v7 | 2021-06-23 | French | Compare |
| v6 | 2021-06-23 | English | Compare |
| v5 | 2021-04-17 | English | Compare |
| v4 | 2021-04-16 | French | Compare |
| v3 | 2021-04-16 | English | Compare |
| v2 | 2021-04-16 | French | Compare |
| v1 | 2021-04-16 | English | Compare |
Showing 1 to 8 of 8